Literature DB >> 21474440

Glucocorticoid-independent repression of tumor necrosis factor (TNF) alpha-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response.

Nicolette J D Verhoog1, Andrea Du Toit, Chanel Avenant, Janet P Hapgood.   

Abstract

TNFα signaling and cytokine levels play a crucial role in cervical immunity and the host response to infections. We investigated the role of liganded and unliganded glucocorticoid receptor (GR) in IL-6 and IL-8 gene regulation in response to TNFα in the End1/E6E7 immortalized human endocervical epithelial cell line. In the absence of glucocorticoids, both decreasing GR protein levels by an siRNA strategy and results with the GR antagonist RU486 suggest a role for the unliganded GR in reduction of TNFα-induced IL-6 and IL-8 mRNA levels in End1/E6E7 cells. Moreover, GR-dependent repression of endogenous IL-6 mRNA as well as a minimal IL-6 promoter-reporter gene is also demonstrated in COS-1 cells in the absence of GR ligand, suggesting a transcriptional mechanism that is not cell-specific. TNFα induced recruitment of both the unliganded GR and GR-interacting protein type 1 (GRIP-1) to the IL-6 promoter. This, together with GRIP-1 overexpression studies, suggests a function for GRIP-1 as a GR co-repressor in this context. TNFα was shown to induce phosphorylation of the unliganded human GR at Ser-226 but not Ser-211, unlike dexamethasone, which induced hyperphosphorylation at both serine residues. Ser-226 is shown to be required for the ligand-independent GR-mediated repression of IL-6 in response to TNFα. Taken together, these results support a model whereby the unliganded GR attenuates TNFα-stimulated IL-6 transcription by a mechanism involving selective phosphorylation and recruitment of the unliganded GR and GRIP-1 to the IL-6 promoter. These findings suggest the presence of a novel autoregulatory mechanism that may prevent overproduction of IL-6 in the endocervix, possibly protecting against negative effects of excessive inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474440      PMCID: PMC3103308          DOI: 10.1074/jbc.M110.193672

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism.

Authors:  L I McKay; J A Cidlowski
Journal:  Mol Endocrinol       Date:  2000-08

2.  Study of nuclear receptor-induced transcription complex assembly and histone modification by chromatin immunoprecipitation assays.

Authors:  Han Ma; Yongfeng Shang; David Y Lee; Michael R Stallcup
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

3.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain.

Authors:  R M Nissen; K R Yamamoto
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

4.  8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein.

Authors:  B G Rowan; N Garrison; N L Weigel; B W O'Malley
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 5.  Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors.

Authors:  K De Bosscher; W Vanden Berghe; G Haegeman
Journal:  J Neuroimmunol       Date:  2000-09-01       Impact factor: 3.478

6.  Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.

Authors:  Martin Dutertre; Carolyn L Smith
Journal:  Mol Endocrinol       Date:  2003-04-24

Review 7.  Modulation of glucocorticoid receptor function via phosphorylation.

Authors:  Naima Ismaili; Michael J Garabedian
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

8.  Ligand-independent coactivation of ERalpha AF-1 by steroid receptor RNA activator (SRA) via MAPK activation.

Authors:  Geneviève Deblois; Vincent Giguère
Journal:  J Steroid Biochem Mol Biol       Date:  2003-06       Impact factor: 4.292

9.  Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells.

Authors:  Dominique Koubovec; Wim Vanden Berghe; Linda Vermeulen; Guy Haegeman; Janet Patricia Hapgood
Journal:  Mol Cell Endocrinol       Date:  2004-06-30       Impact factor: 4.102

10.  Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids.

Authors:  Alejandra Bruna; Marta Nicolàs; Alberto Muñoz; John M Kyriakis; Carme Caelles
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

View more
  29 in total

1.  Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats.

Authors:  Leandro F Vendruscolo; Estelle Barbier; Joel E Schlosburg; Kaushik K Misra; Timothy W Whitfield; Marian L Logrip; Catherine Rivier; Vez Repunte-Canonigo; Eric P Zorrilla; Pietro P Sanna; Markus Heilig; George F Koob
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

2.  Basal p38 mitogen-activated protein kinase regulates unliganded glucocorticoid receptor function in airway smooth muscle cells.

Authors:  Belaid Bouazza; Manel Debba-Pavard; Yassine Amrani; Lauren Isaacs; Danielle O'Connell; Sara Ahamed; Danielle Formella; Omar Tliba
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

Review 3.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

4.  Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug.

Authors:  Samaresh Sau; Sujan Kumar Mondal; Sushil K Kashaw; Arun K Iyer; Rajkumar Banerjee
Journal:  Mol Cell Biochem       Date:  2017-06-05       Impact factor: 3.396

5.  Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab.

Authors:  Anna Leszczynska; Blanca Molins; Estrella Fernández; Alfredo Adán; Santiago Ortiz-Perez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-23       Impact factor: 3.117

6.  Dexamethasone attenuates the embryotoxic effect of endometriotic peritoneal fluid in a murine model.

Authors:  Ryan J Heitmann; Kyle J Tobler; Laurie Gillette; Juan Tercero; Richard O Burney
Journal:  J Assist Reprod Genet       Date:  2015-07-22       Impact factor: 3.412

7.  Lipid raft- and protein kinase C-mediated synergism between glucocorticoid- and gonadotropin-releasing hormone signaling results in decreased cell proliferation.

Authors:  Lancelot Wehmeyer; Andrea Du Toit; Dirk M Lang; Janet P Hapgood
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

8.  Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner.

Authors:  Renate Louw-du Toit; Janet P Hapgood; Donita Africander
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

Review 9.  Glucocorticoid-independent modulation of GR activity: Implications for immunotherapy.

Authors:  Janet P Hapgood; Chanel Avenant; Johnson M Moliki
Journal:  Pharmacol Ther       Date:  2016-06-08       Impact factor: 12.310

10.  Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro.

Authors:  Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.